Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Kearon C and Hirsh J Optimal dose for starting and maintaining low-dose aspirin. 1993 Arch. Intern. Med. pmid:8447706
Chernow B et al. Hormonal responses to graded surgical stress. 1987 Arch. Intern. Med. pmid:3606284
Halt PS et al. Alcohol exacerbates behavioral and neurochemical effects of rat spinal cord trauma. 1992 Arch. Neurol. pmid:1444885
Williams GA et al. Prostacyclin and thromboxane A2 derivatives in rhegmatogenous subretinal fluid. 1983 Arch. Ophthalmol. pmid:6338873
Howes EL et al. Lipopolysaccharide tolerance inhibits eye inflammation. I. Reduced immune complex or lipopolysaccharide effects. 1985 Arch. Ophthalmol. pmid:3156578
Okiji T et al. Involvement of arachidonic acid metabolites in increases in vascular permeability in experimental dental pulpal inflammation in the rat. 1989 Arch. Oral Biol. pmid:2512901
Desideri N et al. Synthesis of some guanylhydrazones and imidazolinylhydrazones as thromboxane-synthase and platelet aggregation inhibitors. 1992 Arch. Pharm. (Weinheim) pmid:1489254
Desideri N et al. N-omega-carbethoxypentyl-4-quinolones: a new class of leukotriene biosynthesis inhibitors. 1997 Arch. Pharm. (Weinheim) pmid:9230527
Lee KS et al. Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action. 2006 Arch. Pharm. Res. pmid:16756082
Hwang GS et al. Effects of Brazilin on the phospholipase A2 activity and changes of intracellular free calcium concentration in rat platelets. 1998 Arch. Pharm. Res. pmid:9868555
Park JW et al. 15,16-dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization. 2008 Arch. Pharm. Res. pmid:18277607
Rosón MI et al. Serotonin hypersensitivity in aorta of two kidney-two clip hypertensive rats: calcium contribution and prostanoids-nitric oxide interactions. 2001 Arch. Physiol. Biochem. pmid:11471069
Luzak B et al. Xanthohumol from hop cones (Humulus lupulus L.) prevents ADP-induced platelet reactivity. 2017 Arch. Physiol. Biochem. pmid:27855519
de la Riva IJ et al. Effect of oral L-arginine administration for three weeks in two kidney-two clip hypertensive rats. 2000 Arch. Physiol. Biochem. pmid:11262599
Kamiya I et al. [The effect of platelet-activating factor (PAF) inhalation on airway responsiveness in beagles]. 1988 Arerugi pmid:3178497
Muramatsu H et al. [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. 2001 Arerugi pmid:11517517
Imai T et al. [Effects of platelet activating factor on release of thromboxane B2 from human granulocytes and platelets]. 1994 Arerugi pmid:7980021
Hashizume M et al. [Clinical study on the inhibitory effect of AA-2414 on platelet function in asthmatic patients]. 1990 Arerugi pmid:2145822
Mizuno M et al. [The changes in plasma beta-thromboglobulin (beta-TG), platelet factor 4 (PF4) and thromboxane B2 (TXB2) after a bronchial provocation test (BPT) with house dust (HD) allergen]. 1991 Arerugi pmid:1831967
Narita S et al. [Studies on thromboxane B2 level in nasal lavage fluid after antigen challenge in patients with allergic rhinitis and guinea pig models]. 1995 Arerugi pmid:8534212
Fukuda Y [Plasma prostaglandin and thromboxane levels in asthmatic children]. 1985 Arerugi pmid:2992423
Narushima M et al. [Studies of adenosine inhalation in asthmatic patients]. 1990 Arerugi pmid:2165388
Hoshino M [Arachidonic acid metabolites in exercise-induced asthma]. 1989 Arerugi pmid:2634372
Nishi K et al. [Inhibitory effect of procaterol (beta 2 agonist) on the release of cyclooxygenase products during antigen-induced bronchoconstriction in the guinea pig in vivo]. 1989 Arerugi pmid:2574030
Satoh H et al. [The effect of a specific antagonist of PAF (CV-3988) on airway hyperresponsiveness induced by ozone exposure in beagles]. 1987 Arerugi pmid:3314797
Horiuchi Y et al. [Studies on changes in histamine levels in the blood of infants and children. Part 7. The time studies of histamine, lipoxygenase metabolites, thromboxe B2 and cyclic AMP release from human platelets and leucocytes on treadmill exercise in asthmatic children]. 1985 Arerugi pmid:3002304
Imai T et al. [Role of thromboxane A2 and prostaglandin I2 in the increase of airway responsiveness in dogs after ozone exposure]. 1992 Arerugi pmid:1520068
Suganuma T et al. [The effect of AH 21-132 on airway hyperresponsiveness induced by ozone exposure]. 1991 Arerugi pmid:1883268
Pinto FC et al. Effect of volume replacement during combined experimental hemorrhagic shock and traumatic brain injury in prostanoids, brain pathology and pupil status. 2015 Arq Neuropsiquiatr pmid:26083885
Venturinelli ML et al. Platelet activation in different clinical forms of the coronary artery disease (role of P-selectin and others platelet markers in stable and unstable angina). 2006 Arq. Bras. Cardiol. pmid:17128313
Whitman SC et al. n-3 fatty acid incorporation into LDL particles renders them more susceptible to oxidation in vitro but not necessarily more atherogenic in vivo. 1994 Arterioscler. Thromb. pmid:8018674
Wang T et al. Synthesis of prostaglandins and thromboxane B2 by cholesterol-fed rabbits. 1991 May-Jun Arterioscler. Thromb. pmid:1903062
Foulon I et al. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. 1993 Arterioscler. Thromb. pmid:8443146
Latta EK et al. Effects of chronic administration of ethanol on platelets from rabbits with diet-induced hypercholesterolemia. Unchanged characteristics and responses to ADP but reduction of enhanced thrombin-induced, TxA2-independent platelet responses. 1994 Arterioscler. Thromb. pmid:8049200
Gross PL et al. Platelet function in Watanabe heritable hyperlipidemic rabbits. Decreased sensitivity to thromboxane A2. 1991 May-Jun Arterioscler. Thromb. pmid:2029501
Tuleja E et al. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. 2003 Arterioscler. Thromb. Vasc. Biol. pmid:12730088
Bröijersén A et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9081681
Mori TA et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9081682
Davi G et al. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9409316
Hsiao G et al. Protective mechanisms of inosine in platelet activation and cerebral ischemic damage. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15976325
Davì G et al. Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15472127
Byrne A et al. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9409315
Sheu JR et al. Triflavin inhibits platelet-induced vasoconstriction in de-endothelialized aorta. 1997 Arterioscler. Thromb. Vasc. Biol. pmid:9437193
Gries A et al. Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. 1996 Arterioscler. Thromb. Vasc. Biol. pmid:8963722
Cayatte AJ et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. 2000 Arterioscler. Thromb. Vasc. Biol. pmid:10894809
Krejcy K et al. Role of nitric oxide in hemostatic system activation in vivo in humans. 1995 Arterioscler. Thromb. Vasc. Biol. pmid:7583590
Michel F et al. Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16385086
Dickneite G and Leithäuser B Influence of antithrombin III on coagulation and inflammation in porcine septic shock. 1999 Arterioscler. Thromb. Vasc. Biol. pmid:10364091
Chiang N et al. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. 2006 Arterioscler. Thromb. Vasc. Biol. pmid:16293793
Rao GH et al. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. 1983 Jul-Aug Arteriosclerosis pmid:6411052